Pharmacokinetic interaction between oltipraz and dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats

被引:11
作者
Bae, SK
Kim, EJ
Chung, SJ
Kim, SG
Lee, MG
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
关键词
D O I
10.1211/0022357021648
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to report the pharmacokinetic interaction between oltipraz (50 mg kg(-1)) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB, 10 mg kg(-1)) after single intravenous and oral administration to rats. After intravenous administration of oltipraz plus DDB, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of oltipraz was significantly greater (1440 vs 1740 mug min mL(-1)) than that after oltipraz alone. This was not due to slower clearances of oltipraz after oltipraz plus DDB since the total body, renal and nonrenal clearances were comparable between the two groups of rats. It could be due to a decrease in tissue binding of oltipraz by DDB. The apparent volume of distribution at steady state (Vd(ss)) of DDB was significantly smaller (7060 vs 4650 mL kg(-1)) than after oltipraz alone. After oral administration of oltipraz plus DDB, the AUC of olitpraz was also significantly greater (479 vs 583 mug min mL(-1)) than that after oltipraz alone. This was not due to increased absorption of oltipraz from the rat gastrointestinal tract after oltipraz plus DDB but again could be due to a decrease in Vd(ss) of oltipraz by DDB. However, after both intravenous and oral administration, the pharmacokinetic parameters of DDB were comparable between DDB alone and DDB plus oltipraz, indicating that oltipraz did not greatly affect the pharmacokinetics of DDB in rats.
引用
收藏
页码:1241 / 1249
页数:9
相关论文
共 35 条
[1]  
Bae SK, 2001, RES COMMUN MOL PATH, V110, P133
[2]  
BAE SK, 2001, P PHARM SOC KOREA SO, P307
[3]  
Baek MS, 2001, DRUG METAB DISPOS, V29, P381
[4]  
BIEDER A, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1289
[5]  
BUEDING E, 1982, RES COMMUN CHEM PATH, V37, P293
[6]   INDUCTION OF PHASE-I AND PHASE-II DRUG-METABOLIZING ENZYME MESSENGER-RNA, PROTEIN, AND ACTIVITY BY BHA, ETHOXYQUIN, AND OLTIPRAZ [J].
BUETLER, TM ;
GALLAGHER, EP ;
WANG, CH ;
STAHL, DL ;
HAYES, JD ;
EATON, DL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1995, 135 (01) :45-57
[7]   POTENTIAL PITFALLS IN THE CONVENTIONAL PHARMACOKINETIC STUDIES - EFFECTS OF THE INITIAL MIXING OF DRUG IN BLOOD AND THE PULMONARY 1ST-PASS ELIMINATION [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1979, 7 (05) :527-536
[8]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[9]   NEW CALCULATION METHOD FOR MEAN APPARENT DRUG VOLUME OF DISTRIBUTION AND APPLICATION TO RATIONAL DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1067-1069
[10]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546